Stay updated on Nivolumab and Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.
Latest updates to the Nivolumab and Ipilimumab in Melanoma Clinical Trial page
- Check5 days agoChange DetectedMelanoma is removed from the Conditions section and the MedlinePlus Genetics related topic is removed.SummaryDifference0.1%
- Check12 days agoChange DetectedAdded Melanoma as a topic and a Related topics note (MedlinePlus Genetics); clarified that publications are auto-filled from PubMed. Removed the older PubMed publications note and updated the revision to v3.3.2.SummaryDifference0.1%
- Check19 days agoChange DetectedThe funding-status notice at the top of the ClinicalTrials.gov page has been removed; the study details, endpoints, and locations remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check34 days agoChange DetectedMelanoma and MedlinePlus Genetics related topics were removed from the page's related topics section.SummaryDifference0.3%
- Check41 days agoChange DetectedThe page now includes Melanoma and MedlinePlus Genetics under Related Topics, serving as navigation aids and context rather than altering trial content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check48 days agoChange DetectedRemoved the MedlinePlus Genetics topic on Melanoma. This reduces coverage of melanoma-related genetic information on the page.SummaryDifference0.1%
Stay in the know with updates to Nivolumab and Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.